Related Experiment Video
Updated: Jun 29, 2026
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
Molecular pathogenesis and diagnostics of bladder cancer
Anirban P Mitra1, Richard J Cote
1Department of Pathology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA. amitra@usc.edu
Annual Review of Pathology
|October 9, 2008
Summary
Bladder cancer, or urothelial carcinoma, involves cellular process alterations. Molecular tests are crucial for diagnosing bladder cancer, predicting tumor behavior, and guiding targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Bladder cancer (urothelial carcinoma) remains a significant epidemiological challenge with rising incidence.
- It is increasingly understood as a disease driven by alterations in multiple cellular processes.
- Tumor behavior varies, with noninvasive types linked to Ras-MAPK pathway activation and aggressive invasive types to p53 and retinoblastoma pathway alterations.
Purpose of the Study:
- To highlight the molecular underpinnings of bladder cancer subtypes.
- To discuss the role of molecular tests in diagnosing and managing bladder cancer.
- To emphasize the future potential of molecular diagnostics and targeted therapeutics in patient care.
Main Methods:
- Review of existing literature on bladder cancer molecular pathways.
- Analysis of diagnostic and prognostic molecular tests for urothelial carcinoma.
- Discussion of the clinical implications of molecular alterations.
Main Results:
- Noninvasive bladder tumors show Ras-MAPK pathway activation.
- Invasive bladder tumors are associated with p53 and retinoblastoma pathway alterations.
- Molecular tests can detect exfoliated tumor cells and predict tumor behavior.
Conclusions:
- Molecular profiling is essential for understanding bladder cancer heterogeneity.
- Future bladder cancer management will integrate molecular tests for accurate diagnosis, prognosis, and personalized treatment selection.
- Targeted therapeutics based on molecular aberrations hold promise for improved patient outcomes.
